One in Five Men Carries an Inherited Cholesterol Particle Their Standard Lipid Panel Never Measures. The First Drug Built to Lower It Just Missed.
A standard cholesterol panel reports total cholesterol, LDL, HDL and triglycerides. It does not report lipoprotein(a), usually written Lp(a) and pronounced "L-P-little-a." Lp(a) is an LDL-like particle with an extra protein, apolipoprotein(a), wrapped around it, and the amount a person carries is set mostly by genes. About 1 in 5 adults have a level high enough to raise heart attack, stroke and aortic valve risk on its own, independent of LDL. Most of them have no idea, because fewer than 1 in 100 Americans have ever been tested. In 2026 the American College of Cardiology and American Heart Association updated their dyslipidemia guideline to advise measuring Lp(a) once in every adult's lifetime. Then, on September 4, 2026, Novartis announced that pelacarsen, the first Lp(a)-lowering drug to finish a cardiovascular outcomes trial, had cut Lp(a) levels but did not reduce heart attacks, strokes or cardiovascular deaths. This article covers what Lp(a) is, what the risk data in men actually show, what changes the number and what the pelacarsen result does and does not mean.
Key Takeaways: What the Research Shows About Lipoprotein(a)
Lipoprotein(a) is a cholesterol-carrying particle whose blood level is roughly 70 to 90 percent inherited through the LPA gene, so diet and exercise change it very little. About 20 percent of adults have Lp(a) at or above 50 mg/dL (about 125 nmol/L), the level the ACC/AHA guidelines treat as a cardiovascular risk enhancer. In a 2021 UK Biobank analysis of 460,506 people, each 50 nmol/L increase in Lp(a) was linked to an 11 percent higher risk of atherosclerotic cardiovascular disease. The 2026 ACC/AHA dyslipidemia guideline, like European and Canadian guidelines, advises measuring Lp(a) once in a lifetime. Statins do not lower Lp(a) and may raise it by roughly 8 to 20 percent, while experimental RNA drugs such as olpasiran and lepodisiran lower it by more than 90 percent. The Lp(a)HORIZON trial of pelacarsen in 8,323 patients with heart disease lowered Lp(a) but missed its primary endpoint for cardiovascular events, according to topline results released in September 2026.
How Lp(a) Is Spread Across the Population
Approximate share of adults in each Lp(a) band, based on the distribution described in the 2022 European Atherosclerosis Society consensus statement for populations of mostly European ancestry. Roughly 1 in 5 people sit at or above 50 mg/dL (about 125 nmol/L), and about 1 in 100 reach 180 mg/dL or higher. People of African ancestry tend to have higher median levels. Bands are rounded for illustration.
What is lipoprotein(a)?
Lipoprotein(a) is an LDL-like particle that carries cholesterol through the blood and has an extra protein called apolipoprotein(a) attached to it. That extra protein is what makes Lp(a) different from ordinary LDL. Apolipoprotein(a) looks a lot like plasminogen, a protein the body uses to break down blood clots, and researchers think this resemblance may make Lp(a) promote clotting as well as plaque. Lp(a) particles also carry oxidized phospholipids, which drive inflammation inside artery walls and inside the aortic valve. So a single Lp(a) particle may be more damaging than a single LDL particle. A 2024 UK Biobank analysis by Elias Björnson and colleagues in the Journal of the American College of Cardiology estimated that, particle for particle, Lp(a) carried about 6 times the coronary risk of LDL. Because there are far fewer Lp(a) particles than LDL particles in most people, LDL still accounts for more total risk at a population level. The size of apolipoprotein(a) varies from person to person depending on how many "kringle IV type 2" repeats a person inherits in the LPA gene. Fewer repeats mean a smaller protein, more efficient production in the liver and higher Lp(a) levels in the blood.
How common is high Lp(a)?
High Lp(a) is common: roughly 1 in 5 adults have a level at or above 50 mg/dL, or about 125 nmol/L. The 2022 European Atherosclerosis Society consensus statement, led by Florian Kronenberg, estimated that about 20 percent of people of European ancestry fall in this range and that about 1 in 100 have extreme levels above 180 mg/dL (about 430 nmol/L). Lp(a) levels differ by ancestry. Median levels tend to be higher in people of African ancestry and somewhat higher in South Asian populations than in people of European or East Asian ancestry. Whether the same number carries the same risk across groups is still being studied. Men and women have similar Lp(a) levels for most of adult life. Women's levels tend to rise after menopause, while men's levels stay relatively flat with age.
Does high Lp(a) actually raise heart attack risk in men?
High Lp(a) does raise heart attack risk, and the evidence includes both large observational studies and genetic studies that point toward a causal role. In the Copenhagen City Heart Study, published by Pia Kamstrup and colleagues in Circulation in 2008, men with Lp(a) above the 95th percentile had roughly 3 to 4 times the risk of heart attack compared with men below the 22nd percentile. The largest single analysis comes from the UK Biobank. Anurag Patel and colleagues, writing in Arteriosclerosis, Thrombosis, and Vascular Biology in 2021, studied 460,506 middle-aged adults and found that every 50 nmol/L increase in Lp(a) was associated with an 11 percent higher hazard of atherosclerotic cardiovascular disease. The relationship looked roughly linear, with no safe cutoff below which the extra risk disappeared. Genetic studies add weight. People who inherit LPA gene variants that raise Lp(a) have higher rates of coronary disease, a pattern called Mendelian randomization. Because genes are assigned at conception, this design is less likely to be distorted by lifestyle differences. Those findings are why many cardiologists, until September 2026, considered Lp(a) one of the more certain causal risk factors in cardiology.
Relative Heart Disease Risk Climbs Steadily With Lp(a)
Patel and colleagues analyzed 460,506 UK Biobank participants in Arteriosclerosis, Thrombosis, and Vascular Biology in 2021 and found an 11 percent higher hazard of atherosclerotic cardiovascular disease for every 50 nmol/L increase in Lp(a). This line compounds that estimate across the range, with 0 nmol/L set to 1.0. It is a modeled illustration of a roughly linear relationship, not a set of measured group results.
Is Lp(a) linked to aortic valve disease?
Lp(a) is strongly linked to calcific aortic valve stenosis, a stiffening and narrowing of the main valve leaving the heart that becomes more common after age 65. In a 2014 Copenhagen analysis in the Journal of the American College of Cardiology, Kamstrup and colleagues found that people with Lp(a) above the 95th percentile had nearly 3 times the risk of aortic valve stenosis compared with people with the lowest levels. The oxidized phospholipids carried on Lp(a) appear to accelerate calcium deposits in valve tissue. There is no approved drug that slows aortic stenosis, and valve replacement is the only treatment once the narrowing becomes severe. That makes Lp(a) one of the few known modifiable targets, at least in theory, for a condition that currently has no medical therapy.
Who should get an Lp(a) test, and how often?
Most adults should have Lp(a) measured once, and the 2026 ACC/AHA dyslipidemia guideline now advises a single lifetime measurement, matching European and Canadian guidelines. A single test is usually enough because Lp(a) levels are mostly inherited and stay fairly stable through adulthood. Testing matters most for men with a personal or family history of early heart disease, men with a heart attack or stent despite normal LDL, men with familial hypercholesterolemia and men with aortic stenosis. Because Lp(a) is inherited, a high result is also a reason for first-degree relatives, including children, to be tested. The Lp(a) test is a simple blood draw and often costs under 50 dollars when paid in cash, though prices vary. It does not require fasting. A 2023 analysis of US health system records led by Harpreet Bhatia found that fewer than 1 percent of patients had ever had Lp(a) measured.
Why One Test Is Usually Enough
Twin and genetic studies estimate that roughly 70 to 90 percent of the variation in Lp(a) between people is inherited, mostly through the number of kringle IV type 2 repeats in the LPA gene. The upper estimate is shown. Levels settle by early adulthood and stay fairly stable, which is why the 2026 ACC/AHA dyslipidemia guideline, along with European and Canadian guidelines, advises measuring Lp(a) once in a lifetime.
- Inherited (LPA gene)
- Everything else (diet, hormones, kidney, liver)
How do you read an Lp(a) result?
An Lp(a) result is usually read against two thresholds: below 30 mg/dL (about 75 nmol/L) is considered low risk, and at or above 50 mg/dL (about 125 nmol/L) is considered elevated. Values in between are a grey zone where other risk factors carry more weight. Above 180 mg/dL (about 430 nmol/L), the European Atherosclerosis Society considers the lifetime risk roughly comparable to familial hypercholesterolemia. Labs report Lp(a) in two different units, and that causes confusion. Milligrams per deciliter measure the mass of the particles. Nanomoles per liter count the particles. Because Lp(a) particles vary in size, there is no exact conversion, though a factor of about 2 to 2.5 nmol/L per mg/dL is often used as a rough guide. Experts generally prefer the nmol/L assays. Lp(a) is best treated as a risk multiplier rather than a standalone diagnosis. A man with Lp(a) of 150 nmol/L, LDL of 70 mg/dL, normal blood pressure and no diabetes is in a very different position from a man with the same Lp(a), LDL of 160 mg/dL and high blood pressure.
The Lp(a) Cut-Points That Matter, in nmol/L
Labs report Lp(a) either in mg/dL (mass) or nmol/L (particle number). The two units do not convert cleanly because Lp(a) particles differ in size, but a rough factor of 2 to 2.5 is often used. Bars show approximate nmol/L equivalents for the thresholds used by the European Atherosclerosis Society, the ACC/AHA guidelines and the Lp(a)HORIZON trial.
Can diet, exercise or supplements lower Lp(a)?
Diet, exercise and supplements have little effect on Lp(a) in most people. Lp(a) is roughly 70 to 90 percent genetically determined, and lifestyle trials have generally shown small or inconsistent changes. Some studies even found that cutting saturated fat raised Lp(a) slightly while lowering LDL. Several common drugs move Lp(a) a little. Niacin lowers Lp(a) by roughly 20 to 30 percent, but the AIM-HIGH and HPS2-THRIVE trials found no reduction in cardiovascular events from adding niacin to statins, and more side effects. PCSK9 antibodies lower Lp(a) by about 25 percent; in the FOURIER trial, evolocumab cut Lp(a) by a median of 27 percent. Statins tend to raise Lp(a) by roughly 8 to 20 percent according to a 2019 meta-analysis by Sotirios Tsimikas and colleagues in the European Heart Journal, though statins still lower overall cardiovascular risk through LDL. Hormone status also matters. Testosterone therapy and some anabolic steroids lower Lp(a), while thyroid disease and kidney disease can raise it. None of these are used as Lp(a) treatments.
Percent Change in Lp(a) by Intervention
Approximate average change in Lp(a) reported in trials and meta-analyses. Statins tend to nudge Lp(a) up by roughly 8 to 20 percent (midpoint shown). Lifestyle changes barely move it. Niacin and PCSK9 antibodies lower it modestly. The RNA-targeting drugs and the oral agent muvalaplin cut it by 80 to 97 percent. A larger drop on a lab report has not yet been shown to mean fewer heart attacks: pelacarsen missed its outcome endpoint in September 2026.
What happened in the pelacarsen Lp(a)HORIZON trial?
The pelacarsen Lp(a)HORIZON trial did not meet its primary endpoint. Novartis announced on September 4, 2026, that pelacarsen, an antisense drug injected monthly, lowered Lp(a) as expected but did not significantly reduce the combined rate of cardiovascular death, nonfatal heart attack, nonfatal stroke and urgent coronary revascularization compared with placebo. Lp(a)HORIZON enrolled 8,323 patients with established cardiovascular disease and Lp(a) of at least 70 mg/dL, with a prespecified analysis in those at 90 mg/dL or higher. Patients were already on well-optimized background therapy; cardiologists commenting on the topline data noted an average LDL of about 66 mg/dL. In the 2020 phase 2 trial published in the New England Journal of Medicine, the 80 mg monthly dose lowered Lp(a) by about 80 percent. Full results, including the high-Lp(a) subgroup, had not been presented as of early October 2026. Possible explanations include a smaller true benefit than genetic studies predicted, a need for deeper or longer reductions, or the fact that very low LDL in the background may have shrunk the room for added benefit. Until full data are published, the result does not prove that Lp(a) is harmless, but it does mean that lowering the number has not yet been shown to prevent events.
What other Lp(a)-lowering drugs are in development?
Several newer Lp(a)-lowering drugs are in late-stage trials, and some lower Lp(a) further than pelacarsen did. Olpasiran, a small interfering RNA drug from Amgen, lowered Lp(a) by more than 95 percent at the 225 mg dose given every 12 weeks in the OCEAN(a)-DOSE trial published in the New England Journal of Medicine in 2022. Its outcomes trial, OCEAN(a)-Outcomes, is ongoing. Lepodisiran, an RNA drug from Eli Lilly, reduced Lp(a) by about 94 percent on average over 60 to 180 days at a 400 mg dose in the ALPACA phase 2 trial, published in 2025. Muvalaplin, an oral pill from Lilly that blocks Lp(a) particle assembly, lowered Lp(a) by up to about 86 percent in the KRAKEN trial reported in JAMA in 2024. Zerlasiran from Silence Therapeutics is also in development. None of these drugs is approved by the FDA, and none has yet shown that it reduces heart attacks or strokes. After the pelacarsen result, those outcome trials matter more, not less.
What can a man with high Lp(a) do right now?
A man with high Lp(a) can lower his overall cardiovascular risk now, even though the Lp(a) number itself is hard to change. The usual clinical approach, reflected in the 2022 EAS statement and the ACC/AHA guidance, is to treat Lp(a) as a reason to be more aggressive with the risk factors that can be changed. In practice that often means a lower LDL or apolipoprotein B target, tighter blood pressure control, not smoking, managing blood sugar and maintaining fitness. Some clinicians use a coronary artery calcium scan to see whether plaque has already formed, which can help decide how intensive treatment should be. Men with very high Lp(a) and existing heart disease may be referred to a lipid specialist; in some countries lipoprotein apheresis, a dialysis-like filtering procedure, is used in severe cases. These are decisions for a physician who knows the full picture. The educational point is narrower: one inexpensive blood test reveals an inherited risk that a standard panel misses, and knowing it changes how the rest of the numbers are read.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.